Aarti Drugs Peer Comparison

NSE: AARTIDRUGS | BSE: 524348

₹421.00

₹-9.90 (-2.30%)

As on 01-Oct-2026IST

Market cap

₹3,852 Cr

Revenue (TTM)

₹2,678 Cr

P/E Ratio

20.1

P/B Ratio

2.4

Div. Yield

0.5 %

Edit

	Aarti Drugs	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	3,852	36,872	27,580	16,849	14,385
Revenue (₹ Cr)	2,678	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	191.10	1,018.97	497.77	603.02	270.18
Net Margin (%)	7.13	10.47	20.72	22.63	23.29
RoE (%)	12.77	21.30	28.49	19.61	14.45
Price to Earnings	20.15	36.46	55.41	27.94	52.24
Price-To-Book	2.41	7.05	13.64	4.83	6.94

Income Statement (₹ Cr)

	Aarti Drugs	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	2,677.58	9,683.45	2,371.81	2,590.40	1,108.39
Total Income	2,680.47	9,730.84	2,402.61	2,664.23	1,159.90
Total Expenditure	2,344.26	7,739.53	1,608.91	1,753.71	720.01
EBITDA	333.32	1,943.92	762.90	836.69	388.38
Depreciation	70.71	425.10	98.11	78.88	74.78
EBIT	262.61	1,518.82	664.79	757.81	313.60
Interest	34.37	148.45	26.33	5.43	0.26
Other Income	2.89	47.39	30.80	73.83	51.50
Exceptional Items	-2.09	-27.85	0.00	-25.66	-3.28
Profit before Tax	229.04	1,389.91	669.26	800.55	361.56
Provision for Tax	37.94	370.94	171.48	197.53	91.39
Profit after Tax	191.10	1,018.97	497.77	603.02	270.18

	Aarti Drugs	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	1,548.86	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	0.08	-7.58	0.00	0.00	2.51
Non-Current Liabilities	343.78	723.57	345.47	142.73	50.51
Current Liabilities	922.26	3,912.24	710.20	508.04	169.08
Total Liabilities	2,815.26	9,514.48	2,930.14	4,157.10	2,231.79

	Aarti Drugs	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	1,325.82	3,392.16	1,290.62	1,321.38	957.22
Current Assets	1,467.77	5,612.10	1,483.13	2,649.36	1,250.11
Total Assets	2,815.26	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	574.83	1,204.08	196.61	0.00	0.00
Net Current Assets	545.51	1,699.86	772.93	2,141.33	1,081.04
Contingent Liabilities	331.00	258.92	13.18	4.82	3.76

	Aarti Drugs	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	253.54	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	-173.41	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	-77.44	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	2.69	93.92	-56.08	-69.08	11.28

	Aarti Drugs	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	12.04	25.25	27.50	24.61	18.04
ROE (%)	12.77	21.30	28.49	19.61	14.45
ROA (%)	7.09	11.42	19.48	16.31	12.66
EBIT Margin (%)	9.81	15.68	28.03	29.25	28.29
Net Margin (%)	7.13	10.47	20.72	22.63	23.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Aarti Drugs	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	10.54	18.36	78.33	7.93	-6.72
EBIT Growth (%)	9.85	30.43	303.07	19.88	-26.64
Net Profit Growth (%)	1.22	32.39	182.61	21.66	-24.38
EPS Growth (%)	2.05	36.68	277.72	25.42	-21.99
Book Value Growth (%)	13.14	11.36	22.95	18.43	11.27

	Aarti Drugs	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	19.99	35.71	55.41	27.06	51.78
Price / Book Value	2.41	7.05	13.64	4.83	6.94
Dividend Yield (%)	0.47	0.19	0.16	0.36	0.55
EV/EBITDA	13.25	19.51	35.94	19.20	35.97
Market Cap (₹ Cr)	2,915.22	30,257.56	15,412.11	11,956.86	10,627.92

	Aarti Drugs	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.17	0.05	0.09	0.00	0.00
Short term debt to equity ratio	0.16	0.16	--	--	--
Current Ratio	1.59	1.43	2.09	5.21	7.39
Quick Ratio	1.06	0.82	1.37	3.85	5.46
Interest Coverage	7.66	10.36	26.41	148.49	1,386.30

	Aarti Drugs	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	30.99	26.46	22.82	41.42	41.52
Asset Turnover	0.99	1.09	0.93	0.70	0.52
Receivable days	112.48	88.68	77.32	144.58	169.86
Inventory Days	68.56	84.11	80.83	96.67	97.92
Payable days	105.73	176.65	125.94	135.45	159.68
Cash Conversion Cycle	75.31	-3.86	32.22	105.80	108.11

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.